Curis, Inc.

Good afternoon and welcome to the QRISIS second quarter 2023 business update call. All participants will be in a listen-only mode. Should you need assistance, please signal conference specialists by pressing the star key followed by zero. After the company's prepared remarks, call participants will have the opportunity to ask a question. To ask a question, you may press star then one on your touchtone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Diantha Duvall, QRIS's Chief Financial Officer. Ms. Diantha, please go ahead.

Thank you, and welcome to QRIS's second quarter 2023 business update call. Before we begin, I would like to encourage everyone to go to the investor section of our website at www.QRIS.com to find our second quarter 2023 business update release and related financial tables. I would also like to remind everyone that during the call, we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. For additional details, please see our SEC filings. Joining me on today's call are Jim Denser, President and Chief Executive Officer, and Jonathan Zung, Chief Development Officer. We will also be available for a question and answer period at the end of our call. I'd now like to turn the call over to Jim.

Thank you, Diantha. Good afternoon, everyone, and welcome to QRIS's second quarter business update call. Big news this quarter is, of course, the removal of the partial clinical hold on our take-game leukemia study and getting that done a full quarter faster than we expected. It's a testament to the hard work of our team at QRIS and the strong support of our clinical investigators. I'd like to take this moment to express my gratitude and appreciation to everyone involved. In our discussions with FDA, we were also able to confirm that 300 milligrams BID is the recommended phase two dose for monotherapy in leukemia. With that confirmation, we're excited to announce that we are expanding monotherapy enrollment in the Take Aim Leukemia study at 300 milligrams BID for relapsed refractory patients with spliceosome or FLT3 mutation. In addition, we're working with our clinical investigators on a frontline study combining emavucirtib with azacitidine and venetoclax to treat all patients with AML, regardless of their mutation status. We expect to have data from both the monotherapy and combination studies in 2024. Now let's transition to our TickAim lymphoma study, where we're focusing on patients with primary CNS lymphoma. There's a high unmet need in this patient population, and we believe combining emavucirtib with ibrutinib could potentially address the problem of ibrutinib resistance and provide a meaningful new therapeutic option for these patients. We're currently enrolling patients and expect to have data in 2024. On the financial front, we were able to further strengthen our balance sheet with a $15 million equity financing achieved with no discount and no warrant coverage. I'm sure everyone on this call knows how rare this is in the current market. All in all, it was a terrific quarter for Curis, and we're excited to be back in the clinic at the recommended Phase II dose of 300 milligrams and closely collaborating with our clinical investigators to develop a novel therapeutic that with the potential to be a cornerstone therapy in heme malignancies. With that, I'll turn the call back over to Diantha to review our financial results for the quarter. Diantha?